Skip to main content
SpringerLink
Log in

The Recent National Lipid Association Recommendations: How Do They Compare to Other Established Dyslipidemia Guidelines?

  • Coronary Heart Disease (E Gianos and B Shah, Section)
  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

The National Lipid Association (NLA) recently released recommendations for the treatment of dyslipidemias. These recommendations have commonalities and differences with those of other major societies with respect to risk assessment, lifestyle therapy, targets of therapy, and the use of non-statin agents. In this review, we compare the basic elements of the guidelines from each major society to provide clinicians with a comprehensive document reviewing the key principles of each.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1—executive summary. J Clin Lipidol. 2014;8(5):473–88. The NLA recommendation document is the most recent of the recommendations to be released and is used in our paper to compare other established guidelines.

    Article  PubMed  Google Scholar 

  2. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285(19):2486-97.

  3. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002;106(25):3143-421.

  4. D’Agostino Sr RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6):743–53.

    Article  PubMed  Google Scholar 

  5. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation. 2014;129(25 Suppl 2):S1–45. The 2013 ACC/AHA guideline on the treatment of blood cholesterol is one of the major guidelines reviewed in our paper.

    Article  PubMed  Google Scholar 

  6. http://www.cardiosource.org/science-andquality/hmaoca,practice-guidelines-and-quality-standards/2013-prevention-guideline-tools.aspx.

  7. Lloyd-Jones DM, Leip EP, Larson MG, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation. 2006;113(6):791–8.

    Article  PubMed  Google Scholar 

  8. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–81.

    Article  CAS  PubMed  Google Scholar 

  9. Boekholdt SM, Arsenault BJ, Mora S, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA. 2012;307(12):1302–9.

    Article  CAS  PubMed  Google Scholar 

  10. Grundy SM. An International Atherosclerosis Society position paper: global recommendations for the management of dyslipidemia. J Clin Lipidol. 2013;7(6):561–5.

    Article  PubMed  Google Scholar 

  11. An International Atherosclerosis Society position paper: global recommendations for the management of dyslipidemia–full report. J Clin Lipidol 2014;8(1):29-60. The International Atherosclerosis Society global recommendations for the management of dyslipidemia document is one of the major guidelines reviewed in our paper.

  12. Ridker PM, Buring JE, Rifai N, et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA. 2007;297(6):611–9.

    Article  CAS  PubMed  Google Scholar 

  13. Ridker PM, Paynter NP, Rifai N, et al. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation. 2008;118(22):2243–51. 4p following 2251.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  14. Jellinger PS, Smith DA, Mehta AE, et al. American association of clinical endocrinologists’ guidelines for management of dyslipidemia and prevention of atherosclerosis. Endocr Pract. 2012;18 Suppl 1:1–78. The American association of clinical endocrinologists’ guidelines for management of dyslipidemia document is one of the major guidelines reviewed in our paper.

    Article  PubMed  Google Scholar 

  15. Cook NR, Paynter NP, Eaton CB, et al. Comparison of the Framingham and Reynolds risk scores for global cardiovascular risk prediction in the multiethnic Women’s Health Initiative. Circulation. 2012;125(14):1748–56. 14.

    Article  PubMed Central  PubMed  Google Scholar 

  16. Eckel RH, Jakicic JM, Ard JD, et al. AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 Pt B):2960–84.

    Article  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Laura Flink, James A. Underberg, Jonathan D. Newman, and Eugenia Gianos declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Department of Medicine, Center for the Prevention of Cardiovascular Disease, New York University School of Medicine, New York University Medical Center, 530 First Avenue, Schwartz 4F, New York, NY, 10016, USA

    Laura Flink, Jonathan D. Newman & Eugenia Gianos

  2. Department of Medicine, Center for the Prevention of Cardiovascular Disease, New York University Medical Center, 317 East 34th street, Floor 7, New York, NY, 10016, USA

    James A. Underberg

  3. Division of Cardiology, Department of Medicine, New York University School of Medicine, New York University Medical Center, 227 E. 30th St., TRB Room 853, New York, NY, 10016, USA

    Jonathan D. Newman

  4. Division of Cardiology, Department of Medicine, New York University School of Medicine, New York University Medical Center, 530 First Avenue, Schwartz 4F, New York, NY, 10016, USA

    Eugenia Gianos

Authors
  1. James A. Underberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jonathan D. Newman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Eugenia Gianos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eugenia Gianos.

Additional information

This article is part of the Topical Collection on Coronary Heart Disease

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Flink, L., Underberg, J.A., Newman, J.D. et al. The Recent National Lipid Association Recommendations: How Do They Compare to Other Established Dyslipidemia Guidelines?. Curr Atheroscler Rep 17, 15 (2015). https://doi.org/10.1007/s11883-015-0494-9

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11883-015-0494-9

Keywords

Search

Navigation